Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed is a malononitrile oxime ether compound having a novel structure as shown in the general formula I. Respective substituents in the general formula I as defined in the specification. ##STR00001## The compound of the general formula I exhibits an excellent microbicidal activity, and can effectively prevent and treat plant diseases caused by bacteria and fungi. Also provided is a use of the compound of the general formula I as a microbicide in the agricultural and other fields.

The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2):

##STR00001## or a salt thereof,
wherein R.sup.1 is hydrogen, a C.sub.1-50 alkyl, preferably a C.sub.1-15 alkyl, more preferably a C.sub.10-15 alkyl, which may be saturated or contain one or more double and/or triple bonds, and/or which may contain one or more functional groups, the functional group being preferably selected from the group consisting of an alkoxy group, a secondary, or tertiary amine, a thioether, an acyloxy group, an acylamido group, a phosphorus containing functional group, a carboxyl group, or a carbonyl group, with a compound of formula (3):

##STR00002##

wherein the bond represents a double or a single bond, W is C, or C(OR.sup.4), Z is O, or OR.sup.5, provided that: when W is C, the bond is a double bond and Z is O, or when W is C(OR.sup.4), the bond is a single bond and Z is OR.sup.5, and
wherein R.sup.2 and R.sup.3 are independently selected from a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein one of R.sup.2 and R.sup.3 is hydrogen, and the other rest is a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein R.sup.2 and R.sup.3 may form a cyclic structure, R.sup.4 and R.sup.5 are independently selected from a C.sub.1-6 alkyl, a cycloalkyl, or an aryl, each of which may be substituted or unsubstituted.

The invention relates to an improved method for the preparation of alkylsalicylaldehyde or its corresponding metallic salts. The invention also relates to a method for the preparation of alkylsalicylaldoxime by reacting said alkylsalicylaldehyde or its corresponding metallic salts with hydroxylamine or its salt. The invention also relates to a method for extracting a metal in an aqueous solution containing dissolved metal.

The invention relates to an improved method for the preparation of alkylsalicylaldehyde or its corresponding metallic salts. The invention also relates to a method for the preparation of alkylsalicylaldoxime by reacting said alkylsalicylaldehyde or its corresponding metallic salts with hydroxylamine or its salt. The invention also relates to a method for extracting a metal in an aqueous solution containing dissolved metal.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The invention relates to an improved method for the preparation of alkylsalicylaldehyde or its corresponding metallic salts. The invention also relates to a method for the preparation of alkylsalicylaldoxime by reacting said alkylsalicylaldehyde or its corresponding metallic salts with hydroxylamine or its salt. The invention also relates to a method for extracting a metal in an aqueous solution containing dissolved metal.